The Global Difficile Infections Clostridium Difficile Associated Disease Industry is projected for steady growth, according to a recent analysis by Future Market Insights (FMI). The market is estimated to reach a value of US$809 million in 2023. Looking ahead, it’s anticipated to climb at a Compound Annual Growth Rate (CAGR) of 6% from 2023 to 2033.
A health risk associated with the spore-forming bacterium “Clostridium difficile” present in the digestive system is Clostridium difficile infection (also known as CDI). Known to be one of the main causes of diarrhea brought on by antibiotics, this illness can produce symptoms that range from moderate, self-limiting diarrhea to severe diarrhea, pseudomembranous colitis, and possibly deadly fulminant colitis.
The burgeoning demand for antimicrobial drugs is expected to be a key driver propelling growth in the Clostridium difficile infection therapeutics market. Furthermore, the global demographic shift towards an aging population is poised to be a significant contributor to the expansion of the clostridium difficile infection treatment market. The convergence of contemporary lifestyles, advanced medical systems, and continuous technological progress is anticipated to fuel substantial growth in the sector in the years to come.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16263
Since the infection is becoming less common, the market for clostridium difficile infection treatments in European countries is shrinking. In Europe, the number of fatalities caused by healthcare-related CDI is estimated to be 3,700 per year. Because of the presence of mandatory monitoring, adherence to isolation, hygiene practices, and sanitation protocols, along with the tracking of antibiotic prescriptions, has advanced.
Key Takeaways from the Global Difficile Infections Clostridium Difficile Associated Disease Industry Study
- Global difficile infection treatment worth to reach US$ 1,448.75 Million by 2033
- Clostridium difficile infection was most common in the United States, representing nearly 70% of all cases.
- In Europe, the number of fatalities caused by healthcare-related CDI is estimated to be 3,700 per year.
- Clostridium difficile infects approximately half a million North Americans each year, according to the Centers for Disease Control (CDC).
- In North America, nearly 29,000 deaths occur within one month of being diagnosed with C. difficile.
Grab Your Report on Discount Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16263
Global Difficile Infections Clostridium Difficile Associated Disease Industry Competition
- Thermo ScientificTM XpectTM difficile Toxin A/B Test, launched by Thermo Fisher Scientific Inc. in September 2021, detects Clostridium difficile toxins A and B in human fecal specimens. It combines superior clinical efficiency with a straightforward three-step procedure.
- The TOX A/B QUIK CHEK ® test from Tech Lab is a rapid enzymatic immunoassay that was released in February 2021. Antibodies against C. difficile toxins A and B are used in the test. A Response Window with two stripes is included in the device. A toxin A and B test line is denoted by one stripe. The monitoring line is the other striped line.
Top 10 Global Difficile Infections Clostridium Difficile Associated Disease Industry Key Companies Profiled:
- Merck & Co. Inc.
- Baxter International Inc.
- Sanofi S.A
- Pfizer Inc.
- Novartis AG
- Astellas Pharma
- Eli Lily & Company
- AstraZeneca
- Actelion Pharmaceuticals Ltd.
- Mylan N.V
Buy The Full Report Now!
https://www.futuremarketinsights.com/checkout/16263
Key Segments Profiled in the Global Difficile Infections Clostridium Difficile Associated Disease Industry Survey
By Treatment:
- Antimicrobial Therapy
- Faecal Microbiota Transplantation
By Drug Type:
- Metronidazole
- Vancomyci
- Fidaxomicin
By End User:
- Hospital
- Pharmacies
- ASCs
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
